HNRNPR

Across TCGA pan-cancer cohorts, HNRNPR Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HNRNPR data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher HNRNPR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HNRNPR expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

PAAD, LIHC, and SARC are the cancer types where HNRNPR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	II,III,IV	0.146	0.557	<.001	24	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
SARC	OS	Median	All	0.174	0.745	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	1.000	0.390	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HNRNPR–PAAD (OS)

Open the PAAD breakdown →